Medpace Holdings, Inc. MEDP Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Revenue by Product | |||||
| AVAI | $134.94M-13.8% | $156.46M-4.2% | $163.31M+38.4% | $118.03M+6.4% | |
| Cardiology | $254.84M+40.0% | $181.98M+13.7% | $160.06M+1.3% | $157.94M+29.9% | |
| Central Nervous System | $239.37M+3.9% | $230.45M+19.0% | $193.69M+10.9% | $174.63M+45.9% | |
| Metabolic | $747.59M+14.8% | $651.24M+10.9% | $587.1M+25.5% | $467.8M+28.9% | |
| Oncology | $744.96M+62.8% | $457.54M+21.4% | $376.84M+54.0% | $244.68M+53.0% | |
| Other | $408.55M-5.3% | $431.38M+6.6% | $404.84M+36.4% | $296.91M+11.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Medpace Holdings, Inc. break its business down?
- Medpace Holdings, Inc. (MEDP) reports total revenue by product across 6 parts — AVAI, Cardiology, Central Nervous System, Metabolic and Oncology. Each is extracted from the segment footnotes and tracked over time.
- Where does Medpace Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Medpace Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
